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Abstract A routine part of the process for developing
National Institute for Health and Care Excellence (NICE)
medical technologies guidance is a submission of clinical
and economic evidence by the technology manufacturer.
The Birmingham and Brunel Consortium External
Assessment Centre (EAC; a consortium of the University
of Birmingham and Brunel University) independently
appraised the submission on the EXOGEN bone healing
system for long bone fractures with non-union or delayed
healing. This article is an overview of the original evidence
submitted, the EAC’s findings, and the final NICE guid-
ance issued.
Key Points for Decision Makers
The clinical evidence supports the use of EXOGEN bone
healing system in non-union long bone fractures; i.e.,
fractureswhich have not healedafter 9 months. Theuseof
EXOGEN in these cases is associated with a cost saving of
£1,164 per patient, due to the avoidance of surgery.
There is substantial uncertainty surrounding the use
of EXOGEN bone healing system for the treatment
of delayed union long bone fractures; i.e., those
showing no radiological evidence of healing after
3 months. The uncertainty surrounding the rate of
bone healing and the necessity of surgery results in a
range of potential cost consequences, some of which
are cost saving and some which are not.
1 Introduction
This article presents a summary of the External Assessment
Centre (EAC) report commissioned by the National Institute for
Health and Care Excellence (NICE) for the EXOGEN ultra-
sound bone healing system for long bone fractures with non-
union or delayed healing. It is part of a series of NICE Medical
Technology Guidance summaries being published in Applied
Health Economics and Health Policy under the remit of NICE’s
Medical Technology Evaluation Programme (MTEP) [1–4].
2 The Decision Problem
2.1 Disease Overview
This guidance relates to long bone fractures with non-union
or delayed healing. For the purpose of this evaluation, long
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bones were defined as the humerus, ulna, radius, femur,
tibia and fibula. The time that it takes for a fracture to heal
varies from patient to patient. ‘Delayed union’ is said to
occur when there is no radiological evidence of healing
within 3 months of fracture. ‘Non-union’ is established
when 9 months have elapsed since the original fracture,
with no visible signs of healing in the past 3 months. Delay
in fracture healing reduces patients’ quality of life and
general well-being. Treatment may be long and complex,
resulting in high costs for the NHS. Donaldson et al. [5]
used data from the Health Survey for England 2002–2004
to estimate the incidence of long bone fractures at 1.2 and
0.8 per 100 person-years for men and women respectively,
about 5–10 % of which will not heal as expected [6].
2.2 Current Treatment Options
Patients are usually treated immediately after fracture, with
open or closed reduction (realignment of the bone ends).
The limb is immobilised using a plaster or splint, and
possibly with insertion of internal or external fixings.
X-rays are used to verify alignment of the bone and to
assess progress towards healing through bridging of the gap
between the fractured bone ends with new bone cortex.
Patients not showing progression to healing by 3 months
(delayed union) do not usually receive further surgery at
this stage unless they have particular indications, such as
an unstable or misaligned fracture or a large inter-fragment
gap. Surgery may take place between 3 and 9 months after
fracture, but clinical practice varies and decisions about the
timing of surgery are made on an individual patient basis.
If the bone fails to heal by 9 months after the original
injury (non-union), surgery will usually be required. Sur-
gery for delayed or non-union usually involves internal or
external fixation and bone grafting (with harvesting from
the patient’s iliac crest).
2.3 EXOGEN Ultrasound Bone Healing System:
Device
The EXOGEN ultrasound bone healing system (referred to
hereafter as EXOGEN) is manufactured by Smith and
Nephew. It delivers low-intensity pulsed ultrasound waves,
and is licensed for healing non-union fractures and accel-
erating the healing of fresh fractures [7]. It is claimed to
promote bone healing by stimulating the removal of old
bone, increasing the production of new bone and increasing
the rate at which fibrous matrix at a fracture site is con-
verted to mineralised bone. Successful use of EXOGEN
may eliminate the need for surgery and its associated
complications. Quicker healing may also have a positive
impact on a patient’s quality of life and functional capacity.
Long bone fractures are suitable for treatment if the
fracture is stable, well aligned and well reduced. It is not
indicated for use in fractures of the skull or vertebrae, or in
children or adolescents due to skeletal immaturity [7].
EXOGEN is available as two disposable devices. The
EXOGEN 4000? is intended for use in patients with non-
union fractures (fractures that have failed to heal after
9 months). The device delivers a minimum of 191 treat-
ments (more than 6 months’ treatment). The EXOGEN
Express is intended for use in patients with delayed healing
fractures (fractures that have no radiological evidence of
healing after 3 months). It delivers a maximum of 150
treatments (less than 5 months’ treatment).
The devices consist of a main operating unit with a
permanently connected transducer and a separate fixture
strap. The strap is placed around the fractured bone, cou-
pling gel is applied to the transducer head and the trans-
ducer is secured directly over the fracture site by a fixture
on the strap. If the patient’s limb is immobilised in a cast, a
hole is cut to allow access of the transducer to the skin. The
device is programmed to deliver ultrasound in 20-minute
sessions, self-administered daily by the patient in their
home [7].
2.4 National Institute for Health and Care Excellence
Scope
The scope specified by NICE defined the decision problem
as follows [7]:
• Population: Patients with long bone fractures with non-
union (failure of healing after 9 months) or delayed
healing (no radiological evidence of healing after
approximately 3 months).
• Intervention: EXOGEN ultrasound bone healing
system.
• Comparator: Surgical treatment with internal or exter-
nal fixation, and with or without bone grafting.
• Outcomes: Bridging on radiograph (three out of four
cortices bridged); fracture healing time; return to
painless weight bearing; avoidance of further surgery,
and device-related adverse events.
3 External Assessment Centre Review
The Birmingham and Brunel Consortium was commis-
sioned by NICE to act as the EAC in the assessment of
EXOGEN. The EAC’s role is to review and critique the
sponsor’s submission, and to produce a report for the
Medical Technologies Advisory Committee (MTAC).
As per NICE requirements, the submission on the EX-
OGEN device, from Smith and Nephew (the sponsor), was
based on the decision problem defined in the scope, and
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followed a set template [8]. The submission comprised a
description of the technology under assessment and the
clinical context of its use, followed by a review of the
available clinical literature relating to the effectiveness of
the intervention and comparator technologies; and an
economic submission, with a review of relevant economic
evidence, a de novo cost analysis, and a spreadsheet model.
3.1 Clinical Effectiveness Evidence
The clinical evidence submitted by the sponsor was based
on 18 studies. There were four randomised control trials
(RCTs): two comparing EXOGEN with placebo (sham
device) in delayed union of long bone fractures; one
comparing surgery with shockwave (which is a different
but related intervention) in long bone non-union fractures;
and one comparing two different types of graft in surgery
for non-union patients. Another non-randomised study
compared different types of surgery [9]. The comparisons
in the surgical studies were not relevant to the decision
problem defined in the scope, and so were treated as case
series for the purposes of the evaluation. The remaining 13
studies were case series. The sponsor classified four of the
case series [10–13] as ‘self-paired’ studies, as the partici-
pants were diagnosed with a non-union fracture with no
expectation of healing and EXOGEN was the only change
in the treatment regimen.
No evidence was found comparing EXOGEN directly
with surgery in the treatment of delayed or non-union
fracture. For non-union fractures, there were independent
estimates of healing rates associated with both EXOGEN
and surgery available from non-comparative case series.
The majority of studies reported fracture healing rate and
time, but evidence on the other outcomes requested in the
scope (evidence of bridging on radiograph, return to
painless weight bearing, avoidance of further surgery, and
device-related adverse events) was limited. The age of
study participants varied (13–92 years), and follow-up
times ranged from 2 months to 6 years. None of the studies
submitted had been carried out in the UK.
For non-union long bone fracture, Mayr et al. [14]
reported a mean healing rate of 84 % (216 out of 256) and
mean healing time of 5.3 months from an international
register of patients treated with EXOGEN. Similarly, Ge-
bauer et al. [10] presented a healing rate of 90 % for a case
series of 51 patients with a minimum fracture age of
8 months treated with EXOGEN. Mean healing time in this
latter cohort was 178 days (ranging from 86 to 375 days). A
third case series reported a mean healing rate of 66 % and
mean healing time of 5.9 months with EXOGEN (range
2.9–12.5 months) [11]. For non-union long bone fractures
treated by surgery, healing rates ranged from 62 to 100 %,
and healing time from 2.25 [15] to 6 months [16].
The principal trial used to provide evidence of clinical
effectiveness in delayed union was Schofer et al. [17], an
RCT of 101 patients with delayed healing fractures of the
tibia (defined as lack of clinical and radiologic evidence of
union, bony continuity or bone reaction at the fracture site
no less than 16 weeks from the index injury or the most
recent intervention) treated by EXOGEN (n = 51) or pla-
cebo (n = 50). There was no significant difference
between the groups in healing rate (judged by clinician
criteria for healing, not otherwise described) over a
4-month follow-up period: 65 % (33/51) versus 46 % (23/
50), hazard ratio 1.69 (p = 0.07). However, significant
improvements in bone mineral density and bone gap area at
the fracture site (both indicators of progression towards
healing) were reported. Mayr et al. [14] reported on 696
patients from the EXOGEN registry with delayed union
(3–9 months post-fracture). In this group, 90 % of all long
bone fractures healed, with an average reported healing
time of 4.4 months. Another case series [11] reported a
healing rate of 83 % (follow up not stated) among 40
patients treated with EXOGEN. No studies reporting post-
surgery healing rates in patients with delayed healing long
bone fractures were presented by the sponsor.
The sponsor cited evidence of adverse events from the
Manufacturer and User Facility Device Experience
(MAUDE) database. Over a 1-year period (April 2011–
April 2012), when approximately 55,000 EXOGEN devi-
ces were used by patients in the USA, it reported three
incidences of skin irritation due to sensitivity to the cou-
pling gel and one report of increased chest pain caused by
potential interference with a cardiac pacemaker. No clini-
cal study reported device-related adverse events and no
significant safety concerns were identified in relation to
EXOGEN. In contrast, several surgical papers reported
adverse events, including postoperative wound infection,
osteomyelitis and pain.
3.1.1 Critique of Clinical Effectiveness Evidence
The EAC noted that the sponsor had not always followed
recommended practice in searching for clinical evidence.
For example, of the databases recommended within the
MTEP sponsor’s submission (MEDLINE, EMBASE,
MEDLINE In-Process and the Cochrane Library), only
MEDLINE via Pubmed was searched, increasing the risk
of publication bias. However, the EAC found a similar
yield on repeating and extending the sponsor’s search
strategy to include EMBASE and CENTRAL, and did not
identify any relevant clinical studies—published or
unpublished—which had not been included in the spon-
sor’s submission.
Overall, the EAC considered the inclusion criteria used
by the sponsor for the selection of studies to be consistent
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with the decision problem and appropriate. One of the
studies included by the sponsor [18] was excluded by the
EAC, because it reported outcome measures outside the
scope. The EAC noted substantial heterogeneity between
studies. The patient population varied in terms of age,
fracture age, fracture type, and smoking status. The posi-
tion of long bone fractures also varied—the most common
were the tibia and femur. The definitions given of delayed
union and non-union also varied between studies, some
falling outside the scope. In addition, the variation in study
location (conducted in twelve countries, and not including
the UK) may have implications in terms of transferability
to an NHS context, given the different characteristics
exhibited by different healthcare systems. This heteroge-
neity was cited by the sponsor as the reason for not
undertaking a meta-analysis. Having reviewed the sub-
mitted papers, the EAC agreed that a meta-analysis would
not be appropriate.
The EAC agreed, broadly, with the absolute healing
rates the sponsor quoted for EXOGEN, (90 % [87–92 %]
and 84 % [80–89 %] for delayed and non-union, respec-
tively [14]). These estimates came from a large registry
study, which used definitions of delayed union and non-
union appropriate to the scope, and reported results sepa-
rately for different long bones. However, the EAC could
not fully support the sponsor’s claim that EXOGEN
achieved faster progression to healing than placebo in the
case of delayed union. This was because the trial on which
this claim was based (Schofer et al. [17]) included patients
who, according to the scope, would be defined as non-
union (more than 9 months post-fracture), as well as
delayed union fractures (3–9 months post-fracture). In
addition, although intermediate measures of bone healing
(bone marrow density and bone gap) were significantly
better among the EXOGEN group, differences in actual
healing rates were not statistically significant.
The EAC also concluded that it was difficult to compare
healing rates between surgery and EXOGEN in non-union
fractures, due to differences in the duration of follow-up.
These different lengths of follow-up also made it difficult
to summarise and draw any conclusion across the range of
surgery studies, despite the fact that most reported high
rates of healing.
Regarding adverse events, the EAC agreed that none
were reported in the included clinical trials, and that there
were few reports of possible device-related adverse events
from the MAUDE database. Some details surrounding the
sponsor’s search strategy for adverse events were not felt to
be transparent; for example, searches of internal EXOGEN
complaint databases. No explanation was given of why the
search was restricted to the period April 2011–12. Fur-
thermore, the EAC felt that EMBASE, the Cochrane
Library and MEDLINE In Process should have been
searched, in addition to PubMed. Despite this, the EAC did
not identify any additional reports of adverse events from
these other sources.
3.2 Economic Evidence
The sponsor identified three economic studies related to the
decision problem, including a cost-effectiveness analysis
[19] and two costing studies [20, 21]. The two models used
by the sponsor for the cost analysis in delayed and non-
union were adapted for submission from a model devel-
oped by Taylor et al. [19]. This was a cost-effectiveness
analysis comparing different treatment options for fresh
tibial fractures (which was not in the NICE scope) and also
comparing surgery with ultrasound for delayed union. The
analysis was based on a Markov model, using monthly
cycles over a horizon of 1 year. It adopted an NHS per-
spective and costs were estimated at 2005/6 prices. The
study concluded that for delayed union fractures, the most
cost-effective strategy was to postpone surgery in favour of
a course of ultrasound therapy, resulting in an equivalent
rate of healing at a lower cost (£3,926 for EXOGEN and
£6,718 for surgery.)
The sponsor’s submitted cost models adopted an NHS
perspective in 2012 prices. For non-union fractures, the
submitted cost model evaluated the associated costs and
consequences of using EXOGEN (4,000?) at diagnosis of
non-union, followed by further surgery if the fracture did
not heal within 6 months. The comparator was surgery at
diagnosis of non-union fractures, followed by repeat sur-
gery if the fracture had not healed within 6 months. The
model contained four health states: non-union fracture;
healed fracture; infection and post-infection. All patients
began in the non-union fracture health state, receiving
either treatment with EXOGEN or surgery. If healing had
not occurred within 6 months, it was assumed that further
surgery was needed. Only patients in the surgery arm were
considered at risk of infection. A similar cost model was
submitted for delayed union fractures, which contained five
health states: delayed union fracture; healed fracture; non-
union fracture; infection and post-infection.
In the delayed healing model, healing rates at 4 months
were estimated at 92 % in the EXOGEN (Express) arm
[14] and 65 % in the surgery arm [17]. These rates were
extrapolated over a 6-month period. In the non-union
model, healing rates for both the EXOGEN and surgery
arms were estimated at 86 % at 6 months [10]. A monthly
infection rate of 1.4 % was used to inform transitions to the
infection state following surgery for non-union [22]. Costs
were estimated using a micro-costing approach. Evidence
on resource use was taken from a range of sources,
including expert opinion and existing NICE guidance—The
Management of Hip Fracture in Adults (CG124) [23]. The
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sources for unit costs included existing NICE guidance
[23], personal correspondence with the sponsor, expert
opinion, and existing published cost estimates.
The results of the sponsor’s base-case analyses found
EXOGEN to be cost saving for both delayed union (cost
saving of £684 relative to control) and for non-union (cost
saving of £2,310 relative to surgery). Deterministic sensi-
tivity analysis was carried out to explore the impact of
parameter uncertainty on the incremental cost of EXO-
GEN, varying the healing and infection rates. For the non-
union model, EXOGEN remained cost saving for all sce-
narios tested. For the delayed union model, EXOGEN
ceased to be cost saving when its healing rate was reduced
from 92 % to less than 82.8 % (assuming a rate of 69 % for
the control group).
3.2.1 Critique of Cost Evidence
The search methods used by the sponsor to identify eco-
nomic evidence were run on PubMed only. The EAC noted
that a broader strategy, using MEDLINE and EMBASE, as
well as searching NHS EED or EconLit is usually recom-
mended. In addition, the searches were limited to English
language (as with the searches for clinical evidence), which
may possibly have led to relevant studies being overlooked.
The EAC, however, did not find any additional relevant
studies when running these additional searches. The studies
included by the sponsor were all consistent with the scope
of the study and the clinical evidence.
The EAC noted a lack of clarity in the submission sur-
rounding certain aspects of model development; for
example, how expert opinion was elicited when checking
the face validity of modelling and the clinical pathway. The
EAC questioned the use of certain sources used in the
models to identify and value resources, in particular the use
of existing NICE clinical guidelines on hip fractures
(CG124) [23], which may not be relevant to this patient
population. The EAC suggested that routinely available
reference cost data might have been a more appropriate
source of cost information to the NHS.
The EAC considered a number of assumptions in the
sponsor’s models to be unjustified, when reviewed in
relation to available evidence. The most significant issue
related to the way in which clinical data was used to esti-
mate healing rates for the models, and the way in which
they were extrapolated over the modelled time horizon.
The EAC accepted the assumption of equal healing rates
for surgery and EXOGEN in the non-union model [10], but
argued that this assumption should be tested in sensitivity
analysis, given the lack of comparative evidence on this
point. However, they challenged the approach taken in the
submitted model for delayed union. This used a healing
rate for the control intervention (wait until non-union for
surgery) from the control arm of the Schofer et al. RCT
[17], while the healing rate for the EXOGEN arm was
taken from the Mayr et al. registry study [14]. This cou-
pling of absolute event rates from independent studies is
susceptible to bias due to differences in the underlying
study populations and methods of outcome assessment: it
‘breaks randomisation’. The EAC argued that a more
robust approach would be to define a ‘baseline risk’ likely
to be relevant for the clinical scenario of interest (e.g., from
the EXOGEN registry data [14]) and then to ‘‘model
backward’’, applying a relative risk adjustment from
comparative trial evidence to estimate risk in the control
arm [17]. The EAC also questioned the way in which
4-month healing rates from the literature had been used in
the delayed union model to estimate the monthly healing
rates, and to extrapolate up to the point of non-union
(6 months after onset of delayed union).
In addition, a number of coding errors were identified in
the submitted model. For example, the submission stated
that non-procedure costs should be equal in both modelled
arms; however, resource use differed between arms in the
non-union model, increasing the costs of each health state
in the surgery arm (by £100 in all health states). The EAC
also noted that the costs of the EXOGEN devices in the
model differed from those stated in the submission.
The EAC made a number of changes to the sponsor’s
models, correcting inconsistencies and errors, and con-
ducting additional sensitivity analysis. The results of the
EAC sensitivity analyses in the non-union model found
that EXOGEN remained cost saving for all scenarios tes-
ted, even when the healing rate with surgery was increased
to over twice that of EXOGEN. However, the magnitude of
the estimated saving was somewhat less than that estimated
in the submission; a base-case saving of £1,164 instead of
£2,310.
In the delayed-union model, the EAC estimated results
for eight scenarios, based on healing curves resulting from
a range of plausible interpretations of the evidence. These
included different sources of healing rates with EXOGEN
(92 % [14] vs. 65 % [17] healed at 4 months after onset of
delayed union), different assumptions about the minimum
time to heal (0 vs. 2 months after onset of delayed union),
and the persistence of the relative benefits of EXOGEN
(hazard ratio of 0 vs. 1.69 [17] between 4 and 6 months
after onset of delayed union). The EAC specified their
‘preferred scenario’, which they considered to be most
plausible. It assumed a healing rate with EXOGEN of 92 %
at 4 months [14], and 1.69 hazard ratio [17] for EXOGEN
versus placebo, with a 2-month delay before healing is
observed, and no persistence of benefit of EXOGEN
treatments after 4 months. Based on this preferred sce-
nario, the EAC estimated that using EXOGEN at delayed
union would be £504 more expensive per patient than
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waiting and then treating surgically if necessary at non-
union. The scenario most favourable to EXOGEN assumes
a healing rate of 46 % for controls and 65 % for EXOGEN
at 4 months, with a 2-month delay before healing is
observed and a persistent enhanced healing rate of EXO-
GEN beyond the end of treatment. Under this scenario,
early use resulted in a cost saving of £390.
3.3 Conclusions of the EAC
The EAC found the clinical evidence supporting the use of
EXOGEN to be limited. There was no direct or indirect
evidence comparing healing rates associated with the
treatment of delayed union fractures of long bones
between EXOGEN and surgery. Consequently, the com-
parison requested in the scope could not be directly
evaluated. However, a randomised trial [17] comparing
early use of EXOGEN (at 3 months) and observation
followed by surgery (if needed at 9 months) was available,
and this was thought to be a clinically appropriate com-
parison in the NHS. This trial found a significant
improvement in measures of bone healing, but was not
powered to detect a difference in healing rates. The trial
was of a good quality, but it included a mix of patients
with delayed union and non-union fractures, with no sub-
group analysis. It therefore could not be said with certainty
how applicable the results were to the specific context of
delayed union. The sponsor reported a cost saving of £684
per patient associated with early use of the EXOGEN
system (at 3 months post-fracture). The EAC found this
result not to be robust to a range of plausible interpreta-
tions of the clinical evidence. Under their preferred ana-
lysis, the EAC estimated that early use of EXOGEN
would cost around £500 more per patient than waiting for
surgery at non-union. However, under an optimistic
interpretation of the clinical data, early treatment would
save about £390 per patient.
There was also no direct evidence comparing healing
rates for EXOGEN and surgery in non-union fractures of
long bones. There was a realistic estimate of absolute
healing rate with EXOGEN from a large registry study
[14], supported by evidence from smaller case series.
Similarly, there were case series estimates of the healing
rate associated with surgery, although these were subject to
more uncertainty due to possible reporting bias. For the
non-union costing model, equal healing rates were assumed
for surgery and EXOGEN. The sponsor reported a cost
saving from the use of EXOGEN in non-union fractures of
around £2,310. This is a much larger difference than in the
delayed union model, as the assumption is that without
EXOGEN all patients with non-union fractures will require
surgery. The EAC estimated a more modest cost saving of
£1,164 per patient with EXOGEN.
Adverse events related to EXOGEN are rare, and it
seems likely to carry a much lower risk of adverse events
than surgery.
4 NICE Guidance
4.1 Draft Recommendations
MTAC met in October 2012. Following review of both the
sponsor’s submission and the EAC report [24], in con-
junction with evidence from expert advisers and patient
testimony, the following provisional recommendations
were issued [25].
1. ‘‘The case for adopting the EXOGEN ultrasound bone
healing system to treat long bone fractures with non-
union is supported by the clinical evidence which
shows high rates of fracture healing and by the cost
consequences of an estimated saving of £1164 per
patient compared with current management, through
avoidance of surgery.
2. There is some radiological evidence of improved
healing when the EXOGEN ultrasound bone healing
system is used for long bone fractures with delayed
healing, but there is high uncertainty about the rate at
which healing progresses between 3 and 9 months
after fracture and about whether or not surgery would
otherwise be necessary. These uncertainties result in a
range of cost consequences, some of which are cost-
saving and others more costly than current
management.’’
4.2 Committee Considerations
The Committee considered it acceptable for the cost
models to be limited to tibial fractures, as the tibia is the
most common long bone for which treatment of non-union
is needed. In the case of delayed healing, the Committee
was advised by the EAC that the methods used by the
sponsor to derive healing rates from the clinical studies
[14, 17] were likely to represent an overestimate of the
effectiveness of EXOGEN relative to the control arms [25].
For long bone fractures with non-union, the Committee
accepted that treatment with EXOGEN resulted in cost
savings. It was also advised that the costs associated with
surgery in the cost models may be underestimated—cost
savings could be even greater in practice. This was also the
case for long bone fractures with delayed healing [25].
Overall, the Committee considered the EAC’s approach
to scenario analyses to be reasonable. For long bone frac-
tures with delayed healing, the Committee accepted the
EAC’s preferred scenario as the most likely. The provisional
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recommendations were subsequently updated to reflect
some of the uncertainty expressed in the EAC’s analysis [24]
and incorporated into the final guidance, as outlined below.
The Committee questioned whether the 12-month time
horizon used in the cost models might be too short, that is,
insufficient to reflect differences between the technologies.
The EAC advised that extending the time horizon would be
likely to have minimal impact on the results—most frac-
tures would heal in 12 months irrespective of intervention
[25].
In terms of equality considerations, the Committee
considered if the fact that the device is self-administered
would render it unsuitable for certain patients. A patient
and clinical expert reassured the Committee that it could be
easily administered by a carer instead, and did not pose an
equality issue [26].
4.3 Final Guidance
The final Medical Technology Guidance document on
EXOGEN ultrasound bone healing system for the treatment
of long bone fractures with non-union or delayed healing
was published by NICE on 9 January 2013 as MTG12. As a
result of changes suggested during the consultation pro-
cess, one of the recommendations was updated to provide
greater clarity surrounding uncertainty about the rate at
which bone healing progresses. The final guidance now
reads:
‘‘There is some radiological evidence of improved
healing when the EXOGEN ultrasound bone healing sys-
tem is used for long bone fractures with delayed healing
(no radiological evidence of healing after approximately
3 months). There are substantial uncertainties about the
rate at which bone healing progresses without adjunctive
treatment between 3 and 9 months after fracture, and about
whether or not surgery would be necessary. These uncer-
tainties result in a range of cost consequences, some cost-
saving and others that are more costly than current
management.’’
5 Challenges
One of the primary challenges identified in the course of
this evaluation was how to interpret limited comparative
evidence of effectiveness. This is not uncommon in the
evaluation of medical devices, where comparative trial
evidence can be scarce. In this case, there was an RCT of
acceptable quality [17], which did provide some compar-
ative evidence of progress towards healing, along with case
series showing healing rates in intervention and control
populations. However, it was not clear how well this evi-
dence applied to a relatively early use of the device in
patients whose fractures might heal without further inter-
vention, due to the heterogeneous nature of the trial pop-
ulation. A further difficulty related to the need to estimate
the shape of the healing curve (not just the proportion of
fractures healed at one given time point) in order to esti-
mate the impact of the device on NHS costs. The EAC
dealt with this challenge by testing a range of scenarios
with differing assumptions. Various plausible interpreta-
tions of the data led to very different cost estimates. The
disparate nature of the study data introduced further
uncertainties. None of the study data were based on
patients in the UK, coming instead from countries as varied
as Egypt, Japan, and the USA. Differences in clinical
practice in different healthcare systems can lead to non-
representative data, which may not be most appropriate for
application to a UK healthcare environment.
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